

IN

Docket No. DRF 3.3-087

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

CERTIFICATION UNDER 37 CFR 1.10

The undersigned hereby certifies that this correspondence, and all documents referred to as being enclosed herewith, is being deposited with the United States Postal Service on this date <u>December 6, 2006</u> in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number <u>EV 504212959 US</u>, addressed to: Commissioner For Patents, P.O. Box 1450,

Alexandria, VA 22313-1450.

Joan Aflisiews

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jagattaran DAS, et al.

Application No.: 10/589,771

Filed: August 17, 2006

For: NOVEL TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS

AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, it is requested that the documents listed on the accompanying Form PTO/SB/08a be considered and made of record in the above-identified patent application. Required copies of these documents are enclosed.

No fee is believed to be due because this Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits. However, the Commissioner is authorized to charge our **Deposit Account No.** <u>50-3221</u> for the required amount in the event that a fee is now due.

Respectfully submitted,

Dated: December 17, 2006

By:

Milagros A. Cepeda Reg. No.: 33,365 Attorney for Applicant

Telephone No.: (908) 203-6505

Dr. Reddy's Laboratories, Inc. 200 Somerset Corporate Blvd., 7th Fl. Bridgewater, NJ 08807

FAX: (908) 203-6515

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
OF Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10589771		
Filing Date		2006-08-17		
First Named Inventor Jagattaran DAS				
Art Unit	·			
Examiner Name	To be assigned			
Attorney Docket Number		DRF 3.3-087		

				U.S	.PATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6054471		2000-04-25	Markus Schm	nutz			
If you wish	n to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	e Add button.			
			U.S.P.	ATENT APPLI	CATION PUE	BLICATIONS			
Examiner Initial*	Publication Number 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			Name of Patentee or Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear			
	1								-
If you wish	to ac	ld additional U.S. Publi	shed Ap	plication citatio	n information	please click the Add	button.		
				FOREIGN PA					
		Foreign Document Number ³	Country Code ²		Publication Date	Name of Patentee Applicant of cited Document	9 01 W	Pages,Columns,Lines vhere Relevant Passages or Relevant igures Appear	T5
	1	0304221	EP	A2	1989-02-22	Merck & Co., Inc.			Ę
	2	03/059894	wo	A1	2003-07-24	Dr. Reddy's Labora	tories		
f you wish	to ad	d additional Foreign Pa					button		
			NON	PATENT LITE	RATURE DO	CUMENTS			

		Application Number		10589771				
INFORMATION PLOST OCCUPA			Filing Date		2006-08-17			
STATEMENT BY APPLICANT (199)		First Named Inventor Jagattaran DAS						
		Art Unit						
		Examiner Name To be assigned						
DECOR	5008	띵)		Attorney Docket Numb	e,r	DRF 3.3-087		
Fyaminer		§)						
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						
	1	Tommoyuki KITAZAKI, et al., Optically Active Antifungal Azoles. X.1) Synthesis and Antifungal Activity of N-[4-(Azolyl) phenyl]-and N-[4-(Azolylmetyl)phenyl]-N'-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl) propyl]-azolones, Chem. Pharm. Bull., 48(12), pp. 1935-1946 (2000).						
	2 Richard J. BOCHIS, et al., Benzylated 1,2,3-Triazoles as Anticoccidiostats, J. Med Chem., 34, pp. 2843-2852 (1991).							
	3	Laszlo HAZAI and Gyula DEAK, Hydrogenation of Substituted 1-Arylisoquinolin-3(2H)-ones to 5,6,7,8-Tetrahydro- and 1,4-Dihydroisoquinolin-3(2H)-ones, J. Heterocyclic Chem., 26, pp. 609-612 (1989).						
If you wish	n to ad	ld add	litional non-patent literature	document citation inform	nation	please click the Add I	button	
				EXAMINER SIGNAT	URE			
Examiner Signature						Date Considered		
*EXAMINE	ER: Ini	itial if	reference considered, whe	ther or not citation is in c	onforn	nance with MPEP 609	. Draw line through a	

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

, `•							
		Application Number	1058977	10589771			
		Filing Date	2006-08-	17			
	FORMATION DISCLOSURE	First Named Inventor	Jagattaran DAS				
(Not for submission under 37 CFR 1.99)		Art Unit					
		Examiner Name	To be assigned	assigned			
1	D' do	Attorney Docket Numb	er DRF 3.3-	087			
	DEC 0 & 2006						
PAR	in of	CERTIFICATION STAT	TEMENT				
Ple	ase 568 7 CFR 1.97 and 1.98 to make the	appropriate selection(s):					
That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1). OR That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).							
	 See attached certification statement. Fee set forth in 37 CFR 1.17 (p) has been submitted herewith. 						
None SIGNATURE							
A s form	ignature of the applicant or representative is n of the signature.	required in accordance	with CFR 1.33,	10.18. Please see CFR 1.4(d) for the			
Signature July of (o ele Date	(YYYY-MM-DD	2006-12-06			
Nan	ne/Print Milagros A. Cepeda	Regis	tration Number	33,365			
This	collection of information is required by 37 C	FR 1 97 and 1 98. Tho	nformation is re	guired to obtain or ratain a han -51 by the			

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.